Neuraxpharm strengthens multiple sclerosis portfolio with the launch of Riulvy® (tegomil fumarate)
Germany is the first European country to launch the product, with further rollouts across Europe to follow
The next-generation oral fumarate therapy is designed to improve gastrointestinal tolerability and support long-term adherence
Barcelona, Spain and Düsseldorf, Germany – 2 October, 2025 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces the launch of Riulvy® (tegomil fumarate) in Germany, the product’s first introduction into the European market.
